NASDAQ · BRVE
Braveheart Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BRVE: Dec 8, 2026
Braveheart Bio, Inc. Common Stock is estimated to report earnings on 12/08/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.91.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.91 | $-0.91 | $-0.91 | 1 |
| Dec 2026 | $-0.03 | $0.35 | $-0.42 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · MarketBeat · The Motley Fool- RTTNews · Sep 9, 5:42 AM EDTBraveheart Posts Wider Loss In Q2 As BHB-1893 Advances In HCM Development(RTTNews) – Braveheart Bio, Inc. (BRVE), a clinical-stage biopharmaceutical company, reported second-quarter results, reflecting a wider net loss for the quarter ended June 30, 2026.
- Fintel · Sep 4, 4:03 AM EDTCantor Fitzgerald Initiates Coverage of Braveheart Bio (BRVE) at OverweightFintel reports that on August 31, 2026, Cantor Fitzgerald initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Overweight recommendation. This coverage initiation by Cantor Fitzgerald was part of a larger cluster of analyst actions occurring on the same day. On August 31,
- Fintel · Sep 4, 4:02 AM EDTJefferies Initiates Coverage of Braveheart Bio (BRVE) with Buy RatingFintel reports that on August 31, 2026, Jefferies initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Buy recommendation.This coverage initiation by Jefferies was part of a cluster of three same-day rating actions for the US-market company on August 31, 2026. All three of
- Fintel · Sep 4, 4:02 AM EDTTD Cowen Initiates Coverage of Braveheart Bio (BRVE) with BuyFintel reports that on August 31, 2026, TD Cowen initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Buy recommendation.This coverage initiation by TD Cowen was one of two identical actions taken by major analyst firms on the same day. On August 31, 2026, the total same-d
- Fintel · Sep 4, 4:01 AM EDTGoldman Sachs Initiates Coverage of Braveheart Bio (BRVE) with BuyFintel reports that on August 31, 2026, Goldman Sachs initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Buy recommendation. This rating action was officially recorded on August 31, 2026, for the US-marketed security, which trades in USD.In the trading session immediatel
- MarketBeat · Aug 31, 1:20 PM EDTInsiders Are Betting Big on These 3 Healthcare StocksInsiders are betting big on pharma in Q3, highlighting opportunities for speculative investors. Speculation is the key word, as these stocks offer risks alongside potentially strong rewards. The question is what is driving the interest from insiders—and how big the potential gai
- The Motley Fool · Aug 10, 3:59 PM EDTBraveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026.
- The Motley Fool · Aug 10, 3:40 PM EDTBraveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close.
- The Motley Fool · Aug 10, 3:11 PM EDTBraveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?CEO Travis Murdoch acquired 83,333 shares at $18.00 per share, representing a total transaction value of $1.5 million.
- BNK Invest · Aug 10, 2:18 PM EDTMonday 8/10 Insider Buying Report: BV, BRVEAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At BrightView Holdings, a filing with the SEC revealed that on Thursday, William L
- RTTNews · Aug 6, 10:30 PM EDTTop Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%(RTTNews) – Today's top gainers in the biotech space include Creative Medical, boosted by a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes; Braveheart, following its IPO; Iovance, after reporting a 66% increase in second-quarter revenue; and Sight Scienc
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Braveheart Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.